Uncategorized

Crossject signs ZEPIZURE® commercialization agreement for northern Europe

Crossject, a specialty pharma company developing needle-free auto-injectors for emergency situations, announces it has concluded a commercialization agreement in northern Europe for its innovative rescue therapy for epileptic seizures ZEPIZURE®, previously known as ZENEO® Midazolam, covering Germany, the UK, Denmark, Sweden, Finland and Norway.

Crossject signs ZEPIZURE® commercialization agreement for northern Europe Read More »

Ono Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV’s AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs

Ono Pharmaceutical Co., Ltd. announced that it has entered into a discovery collaboration agreement with EVQLV, INC, to generate novel antibodies against multiple targets selected by Ono, for the development of innovative antibody drugs.

Ono Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV’s AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs Read More »

Scroll to Top